OrganoTherapeutics

Executive Summary

OrganoTherapeutics is a preclinical-stage biotechnology company pioneering the use of human iPSC-derived midbrain organoids for Parkinson's disease research and drug discovery. Founded in 2019 and headquartered in Leuven, Belgium, the company leverages advanced 3D organoid and assembloid models combined with high-throughput, AI-driven analytics to recapitulate key pathological features of Parkinson's disease in vitro. This platform enables more physiologically relevant screening of therapeutic candidates, potentially accelerating the development of disease-modifying treatments for a large unmet medical need. OrganoTherapeutics' technology addresses the limitations of traditional 2D cell cultures and animal models, offering a human-relevant system for studying neurodegeneration and testing neuroprotective compounds. Currently operating in the pre-clinical stage, OrganoTherapeutics has built a robust proprietary platform and is advancing its internal pipeline of small molecule and gene therapy candidates targeting Parkinson's disease. The company has not yet disclosed total funding or valuation, but its innovative approach positions it as a potential leader in the emerging field of organoid-based drug development. With a strong scientific foundation and increasing industry interest in human-relevant models, OrganoTherapeutics is well-positioned to secure partnerships and funding to drive its programs toward clinical validation. The technology's applicability extends beyond Parkinson's to other neurological and rare diseases, providing multiple avenues for growth and impact.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round65% success
• Q2 2027Research Collaboration with Major Pharmaceutical Company50% success
• Q3 2026Presentation of Preclinical Data at Neuroscience Conference75% success